Allergan plc (NYSE:AGN) insider William Meury sold 58,879 shares of the firm’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total value of $9,457,144.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
William Meury also recently made the following trade(s):
- On Friday, December 1st, William Meury sold 11,807 shares of Allergan stock. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23.
Allergan plc (NYSE:AGN) opened at $164.04 on Friday. The firm has a market capitalization of $54,700.00, a PE ratio of -13.68, a price-to-earnings-growth ratio of 1.16 and a beta of 1.19. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.04 and a quick ratio of 1.88. Allergan plc has a 52-week low of $156.00 and a 52-week high of $256.80.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be given a $0.72 dividend. This is an increase from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a yield of 1.76%. The ex-dividend date is Tuesday, February 27th. Allergan’s payout ratio is currently -23.35%.
A number of analysts have issued reports on the company. Zacks Investment Research raised Allergan from a “sell” rating to a “hold” rating in a research note on Monday, October 23rd. JPMorgan Chase & Co. set a $275.00 price objective on Allergan and gave the stock a “buy” rating in a research report on Sunday, October 22nd. Credit Suisse Group set a $214.00 price objective on Allergan and gave the stock a “buy” rating in a research report on Monday, January 22nd. Vetr downgraded Allergan from a “hold” rating to a “sell” rating and set a $180.97 price objective for the company. in a research report on Monday, January 22nd. Finally, Morgan Stanley reissued a “buy” rating on shares of Allergan in a research report on Wednesday, January 24th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Allergan has an average rating of “Buy” and an average target price of $227.23.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGN. Cable Hill Partners LLC grew its position in Allergan by 255.2% in the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after acquiring an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. grew its position in Allergan by 283.7% in the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after acquiring an additional 400 shares in the last quarter. Avestar Capital LLC acquired a new position in Allergan in the 4th quarter valued at about $113,000. Focused Wealth Management Inc grew its position in Allergan by 4,444.4% in the 4th quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock valued at $134,000 after acquiring an additional 800 shares in the last quarter. Finally, BB&T Investment Services Inc. grew its position in Allergan by 1,308.2% in the 3rd quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after acquiring an additional 641 shares in the last quarter. 79.76% of the stock is owned by institutional investors.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.